Precision BioSciences (DTIL) Price & Analysis

Compare

753 Followers

DTIL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.61 - $11.09

Previous CloseN/A

Volume55.33K

Average Volume (3M)178.30K

Market Cap

$51.63M

Enterprise Value$13.60M

Total Cash (Recent Filing)$62.24M

Total Debt (Recent Filing)$29.45M

Price to Earnings (P/E)2.4

Beta1.19

Next Earnings

Nov 11, 2025

EPS Estimate

-1.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.13

Shares Outstanding11,786,991

10 Day Avg. Volume94,890

30 Day Avg. Volume178,304

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.26

Enterprise Value/Revenue10.78

Enterprise Value/Gross Profit24.07

Enterprise Value/Ebitda-0.18

Forecast

1Y Price Target

$28.38

Price Target Upside494.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPBGENE-HBV has shown favorable safety and proof-of-activity at the lowest dose, supporting continued dose escalation.

Financial StabilityPrecision Biosciences has a cash runway into the second half of 2027, indicating financial stability and the ability to advance its programs.

Regulatory ApprovalsPrecision was granted FDA rare pediatric disease and orphan drug designation for PBGENE-DMD for the treatment of DMD.

Bears Say

Antigen LevelsThere was a compensatory upregulation of antigens (HBsAg) in two patients, causing their levels to return to baseline.

Efficacy ConcernsCurrent dose levels in human trials are significantly lower than those that showed over 90% antigen reduction in animal studies, indicating a gap in efficacy.

Efficacy ReadoutThe efficacy readout is different as liver biopsy is not being conducted in Phase 1 trial.

Precision BioSciences News

Precision BioSciences reports safety, efficacy data for ELIMINATE-B trial cohort

Precision BioSciences (DTIL) announced ELIMINATE-B results as of the data cutoff of July 28. Data include completed Cohort...

9d ago

DTIL

Precision BioSciences granted Orphan Drug Designation for PBGENE-DMD

Precision BioSciences (DTIL) announced that the FDA has granted Orphan Drug Designation for PBGENE-DMD for the treatment of...

23d ago

DTIL

Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status

The FDA granted orphan designation to a treatment of Duchenne muscular dystrophy being developed by Precision BioSciences (DTIL),...

29d ago

DTIL

Precision BioSciences: Promising Clinical Milestones and Strategic Advancements Drive Buy Rating

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating on...

4d ago

DTIL

Precision BioSciences Reports Significant Quarterly Loss

Precision Biosciences ( ($DTIL) ) has released its Q2 earnings. Here is a breakdown of the information Precision...

7d ago

DTIL

Positive Outlook for Precision BioSciences Amid Promising Clinical Trial Data and Strategic Advancements

Analyst Soumit Roy from JonesTrading maintained a Buy rating on Precision BioSciences and keeping the price target at...

9d ago

DTIL

Promising Phase 1 Data and Strong Financial Position Justify Buy Rating for Precision BioSciences’ PBGENE-HBV

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Precision BioSciences, retaining the price target of...

9d ago

DTIL

Precision BioSciences Reports Promising Phase 1 Trial Results

Precision BioSciences ( ($DTIL) ) just unveiled an update. On August 6, 2025, Precision BioSciences announced results from...

9d ago

DTIL

Precision BioSciences announces additional PBGENE-DMD preclinical data

Precision BioSciences (DTIL) announced updated additional preclinical data further validating the scientific rationale supporting the rapid development of...

1M ago

DTIL

Precision BioSciences: Strong Buy Rating Based on Promising Gene Editing Innovations and Market Positioning

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Precision BioSciences (DTIL –...

2M ago

DTIL

Precision granted Rare Pediatric Disease Designation for PBGENE-DMD

Precision BioSciences (DTIL) announced that the FDA has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment...

2M ago

DTIL

Precision BioSciences: Promising Gene Editing Platform Targets Chronic HBV and DMD with Strategic Focus

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Precision BioSciences (DTIL – Research Report). The...

2M ago

DTIL

Precision BioSciences Holds Annual Stockholder Meeting

The latest announcement is out from Precision BioSciences ( ($DTIL) ). On May 28, 2025, Precision BioSciences, Inc....

2M ago

DTIL

Buy Rating for Precision BioSciences: Promising ARCUS-Based Programs and Strong Gene Editing Prospects

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) and...

3M ago

DTIL

DTIL FAQ

What was Precision BioSciences’s price range in the past 12 months?

Precision BioSciences lowest stock price was $3.61 and its highest was $11.09 in the past 12 months.

What is Precision BioSciences’s market cap?

Precision BioSciences’s market cap is $51.63M.

When is Precision BioSciences’s upcoming earnings report date?

Precision BioSciences’s upcoming earnings report date is Nov 11, 2025 which is in 88 days.

How were Precision BioSciences’s earnings last quarter?

Precision BioSciences released its earnings results on Aug 06, 2025. The company reported -$2.13 earnings per share for the quarter, missing the consensus estimate of -$1.5 by -$0.63.

Is Precision BioSciences overvalued?

According to Wall Street analysts Precision BioSciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Precision BioSciences pay dividends?

Precision BioSciences does not currently pay dividends.

What is Precision BioSciences’s EPS estimate?

Precision BioSciences’s EPS estimate is -1.49.

How many shares outstanding does Precision BioSciences have?

Precision BioSciences has 11,786,991 shares outstanding.

What happened to Precision BioSciences’s price movement after its last earnings report?

Precision BioSciences reported an EPS of -$2.13 in its last earnings report, missing expectations of -$1.5. Following the earnings report the stock price went down -1.029%.

Which hedge fund is a major shareholder of Precision BioSciences?

Currently, no hedge funds are holding shares in DTIL

Precision BioSciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-143.89%

Trailing 12-Months

Asset Growth

-34.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Precision BioSciences

Precision BioSciences, Inc. (DTIL) is a biotechnology company that specializes in gene editing and genetic therapies. The company operates primarily in the life sciences sector, focusing on developing innovative solutions for various diseases, including cancer and genetic disorders. Precision BioSciences utilizes its proprietary ARCUS technology, a genome editing platform designed to create precise and efficient edits in DNA, enabling the development of therapies that can potentially transform treatment paradigms. The company collaborates with academic institutions and biopharmaceutical companies to advance its research and therapeutic candidates.

Precision BioSciences (DTIL) Earnings & Revenues

Historic Earnings Reports

DTIL Stock 12 Month Forecast

Average Price Target

$28.38

▲(494.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","61":"$61","16.75":"$16.75","31.5":"$31.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,16.75,31.5,46.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.62,8.879999999999999,13.14,17.4,21.66,25.919999999999998,30.18,34.44,38.699999999999996,42.959999999999994,47.21999999999999,51.48,55.739999999999995,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.62,6.447692307692307,8.275384615384615,10.103076923076923,11.93076923076923,13.758461538461539,15.586153846153845,17.41384615384615,19.24153846153846,21.069230769230767,22.896923076923077,24.724615384615383,26.55230769230769,{"y":28.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.62,4.610769230769231,4.601538461538461,4.592307692307692,4.5830769230769235,4.573846153846154,4.564615384615385,4.555384615384615,4.546153846153846,4.536923076923077,4.527692307692308,4.518461538461539,4.509230769230769,{"y":4.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.37,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >